专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020100043721A 혈압 강하용 약학 조성물 无效
标题翻译：用于降低血液水平的药物组合物
公开(公告)号：KR1020100043721A
公开(公告)日：2010-04-29
申请号：KR1020080102894
申请日：2008-10-21
申请人： 현대약품 주식회사
发明人： 이규현 , 박홍준 , 신창용 , 명창선
IPC分类号： A61K31/4184 , A61K31/44 , A61P9/12
CPC分类号： A61K31/4184 , A61K31/4422 , A61K2300/00
摘要： PURPOSE: A pharmaceutical composition for reducing blood pressure through synergic effect of termisartan and lercanidipine is provided. CONSTITUTION: A pharmaceutical composition for reducing blood pressure contains effective amount of telmisartan and lercanidipine. The pharmaceutical composition contains 5-80 mg of telmisartan and 1.25-20 mg of lercanidipine in a weight ratio of 64 : 1-1 : 4. The pharmaceutical composition is manufactured in the form of oral formulation. The pharmaceutical composition is used for preventing or treating hypertension, cardiac insufficiency, arteria coronaria atresia choanae, ischemic heart disease, ischemic peripheral circulatory system disease, hypertensive renal failure, stroke or artery scleroma.
摘要翻译：目的：提供一种药物组合物，通过协同效应降低血压，因此可用于替拉西定。构成：用于降低血压的药物组合物含有有效量的替米沙坦和氯卡地平。药物组合物含有5-80mg替米沙坦和1.25-20mg重量比为64:1-1:4的氯卡地平。药物组合物以口服制剂的形式制备。药物组合物用于预防或治疗高血压，心功能不全，冠状动脉闭塞性闭锁，缺血性心脏病，缺血性外周循环系统疾病，高血压性肾衰竭，中风或动脉硬化。

2. 发明公开

KR1020120018236A 치환된 피리미디닐 유도체 및 이의 제조방법 无效
标题翻译：取代的吡啶衍生物及其制备方法
公开(公告)号：KR1020120018236A
公开(公告)日：2012-03-02
申请号：KR1020100071657
申请日：2010-07-23
申请人： 현대약품 주식회사
发明人： 박용규 , 방성훈 , 김진웅 , 이한규 , 김재현 , 손창모 , 이준희 , 신창용 , 이종찬 , 이재걸
IPC分类号： C07D403/14 , C07D401/12 , A61K31/506 , A61P3/00
摘要： PURPOSE: A pharmaceutical composition containing substituted pyrimidinyl derivatives for treating metabolic disorders is provided to activate GPR119 and to treat metabolic syndrome and obesity. CONSTITUTION: A substituted pyrimidinyl derivative is denoted by chemical formula 1. In chemical formula 1, Z_1 and Z_3 are N; Z_2 and Z_4 are CH; and L_1 is O. A pharmaceutical composition for treating metabolic disorders contains the compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The metabolic disorders include type I diabetes, type II diabetes, insulin resistance, hyperlipidemis, hypercholesterolemia, and dyslipidemia.
摘要翻译：目的：提供含有用于治疗代谢紊乱的取代嘧啶衍生物的药物组合物以激活GPR119并治疗代谢综合征和肥胖症。构成：取代的嘧啶基衍生物由化学式1表示。在化学式1中，Z 1和Z 3为N; Z_2和Z_4是CH; L_1为O.用于治疗代谢紊乱的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。代谢紊乱包括I型糖尿病，II型糖尿病，胰岛素抵抗，高脂血症，高胆固醇血症和血脂异常。

3. 发明公开

KR1020120011357A 치환된 피리디논 유도체 및 이의 제조방법 无效
标题翻译：取代的吡啶酮衍生物及其制备方法
公开(公告)号：KR1020120011357A
公开(公告)日：2012-02-08
申请号：KR1020100071674
申请日：2010-07-23
申请人： 현대약품 주식회사
发明人： 박용규 , 방성훈 , 김진웅 , 이한규 , 김재현 , 손창모 , 이준희 , 신창용 , 이종찬 , 이재걸
IPC分类号： C07D401/14 , C07D401/12 , A61K31/444 , A61P3/00
CPC分类号： C07D401/14 , C07D213/69 , C07D213/70 , C07D401/12 , C07D413/12
摘要： PURPOSE: A pharmaceutical composition containing a novel compound or pharmaceutically acceptable salt thereof for treaitng metabolism-associated disorders is provided. CONSTITUTION: A substituted pyridinone derivative is denoted by chemical formula 1. A pharmaceutical composition for treating metabolism-associated disorders contains the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The metabolism-associated disorder is obesity type I, diabetes type II or I, insulin resistance, hyperglycemia, or hyperlipidemia. The compound of chemical formula 1 is prepared by reacting compounds of chemical formulas 4 and 5.
摘要翻译：目的：提供含有新化合物或其药学上可接受的盐以代谢相关疾病的药物组合物。构成：取代的吡啶酮衍生物由化学式1表示。用于治疗代谢相关疾病的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。代谢相关疾病是I型肥胖，II型或II型糖尿病，胰岛素抵抗，高血糖或高脂血症。化学式1的化合物通过化学式4和5的化合物反应制备。

4. 发明公开

KR1020100046923A 약학 조성물 无效
标题翻译：药物组合物
公开(公告)号：KR1020100046923A
公开(公告)日：2010-05-07
申请号：KR1020080105967
申请日：2008-10-28
申请人： 현대약품 주식회사
发明人： 이규현 , 박홍준 , 신창용 , 명창선
IPC分类号： A61K31/403 , A61K31/5415 , A61P9/12
CPC分类号： A61K31/403 , A61K9/0053 , A61K31/41 , A61K31/4184 , A61K2300/00 , Y10S514/824
摘要： PURPOSE: A pharmaceutical composition containing ramipril and telmisartan or valsartan is provided to ensure effective blood pressure reduction and to suppress heart damage. CONSTITUTION: A pharmaceutical composition for reducing blood pressure contains effective amount of ramipril and telmisartan or valsartan as an active ingredient. A pharmaceutical composition contains 0.312-5 mg of ramipril and 10-160mg of valsartan. A pharmaceutical composition contains 0.312-5mg and 5-80 mg of telmisartan. The pharmaceutical composition is used in the oral formulation. The pharmaceutical composition is used in treating or preventing hypertension, cardiac insufficiency, arteria coronaria atresia choanae, ischemic heart disease, ischemic peripheral circulatory system disease, hypertensive renal failure, stroke or artery scleroma.
摘要翻译：目的：提供含有雷米普利和替米沙坦或缬沙坦的药物组合物，以确保有效降低血压并抑制心脏损伤。构成：用于降低血压的药物组合物含有有效量的雷米普利和替米沙坦或缬沙坦作为活性成分。药物组合物含有0.312-5mg的雷米普利和10-160mg的缬沙坦。药物组合物含有0.312-5mg和5-80mg替米沙坦。药物组合物用于口服制剂中。药物组合物用于治疗或预防高血压，心功能不全，冠状动脉闭塞性闭锁，缺血性心脏病，缺血性外周循环系统疾病，高血压性肾衰竭，中风或动脉硬化。

5. 发明公开

KR1020100048137A 혈압 강하용 약학 조성물 无效
标题翻译：抗高血糖药物组合物
公开(公告)号：KR1020100048137A
公开(公告)日：2010-05-11
申请号：KR1020080107163
申请日：2008-10-30
申请人： 현대약품 주식회사
发明人： 이규현 , 박홍준 , 신창용 , 명창선
IPC分类号： A61K31/4184 , A61P9/12
CPC分类号： A61K31/4184 , A61K9/0053 , A61K31/401 , A61K31/403 , A61K31/41 , A61K31/4178 , A61K31/4418 , A61K31/451 , A61K2300/00 , Y10S514/824
摘要： PURPOSE: A pharmaceutical composition for reducing blood pressure containing angiotensin II receptor blocker, angiotensin converting enzyme inhibitor, or calcium channel blocker is provided. CONSTITUTION: A pharmaceutical composition for reducing blood pressure contains an angiotensin II receptor blocker of candesartan, losartan, olmesartan, valsartan, irbesartan, or telmisartan; an angiotensin converting enzyme inhibitor of ramipril, lisinopril, or perindopril; and a calcium channel blocker of amlodipine, lacidipine, cilnidipine, or lercanidipine. The composition is used in preventing or treating hypertension, cardiac insufficiency, arteria coronaria atresia choanae, ischemic heart disease, ischemic peripheral circulatory system disease, hypertensive renal failure, stroke or artery scleroma.
摘要翻译：目的：提供一种用于降血压的血管紧张素II受体阻断剂，血管紧张素转换酶抑制剂或钙通道阻断剂的药物组合物。构成：用于降低血压的药物组合物含有坎地沙坦，氯沙坦，奥美沙坦，缬沙坦，厄贝沙坦或替米沙坦的血管紧张素II受体阻断剂; 雷米普利，赖诺普利或培哚普利的血管紧张素转换酶抑制剂; 和氨氯地平，拉西地平，西尼地平或氯卡地平钙通道阻滞剂。该组合物用于预防或治疗高血压，心功能不全，冠状动脉闭锁性闭锁，缺血性心脏病，缺血性外周循环系统疾病，高血压性肾衰竭，中风或动脉硬化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式